European Innovation Council

The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.

David Malo Jean

Director

Past deals in Europe

VSORA

Venture Round in 2025
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

AMT Medical

Series B in 2025
AMT Medical B.V., founded in 2015 and based in Ede, the Netherlands, specializes in developing innovative devices for heart bypass surgery. The company has created the AMT Heart Bypass System, which utilizes the ELANA bypass technique, originally developed by neurosurgeon Prof. Dr. C.A.F. Tulleken and his team. This minimal invasive approach aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, ultimately improving patient outcomes and recovery times. The AMT Heart Bypass System has completed its development and production processes, as well as all pre-clinical trials. A clinical multi-center trial is set to begin in late 2019 or early 2020, marking a significant step in bringing this advanced technology to the medical community.

Sparrow Quantum

Series A in 2025
Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

Marvel Fusion

Series B in 2025
Marvel Fusion is a developer of fusion energy technology focused on providing environmentally friendly and safe energy solutions. Founded in 2019 and based in Munich, Bayern, the company specializes in a laser-based nuclear fusion reactor that utilizes short pulse, high energy, and electrically efficient lasers. This technology aims to commercialize baseload fusion electrical power, enabling consumers to access clean, safe, and reliable energy sources.

Stablepharma

Grant in 2025
Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

Wooptix

Series C in 2025
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

AlzeCure Pharma

Grant in 2025
AlzeCure Pharma AB, established in 2012 and headquartered in Huddinge, Sweden, is a pharmaceutical company dedicated to developing drug therapies for central nervous system disorders. The company's primary focus is on Alzheimer's disease, with a pipeline consisting of five drug candidates based on its NeuroRestore and Alzstatin research platforms. These candidates are in various stages of development, targeting conditions such as sleep disruptions, traumatic brain injuries, neuropathic pain, and eye/ear indications. AlzeCure's team comprises key professionals with complementary expertise, spanning from molecule to man, and the company aims to be an industry-standard incubator for novel projects.

QDI systems

Venture Round in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

QDI systems

Grant in 2025
QDI Systems B.V. is a startup based in Groningen, the Netherlands, specializing in the development of advanced imaging devices for medical applications using quantum dot technology. The company focuses on creating X-ray sensors that deliver high-contrast and high-resolution mammograms, allowing for improved diagnostic capabilities while minimizing radiation exposure for patients. QDI Systems emphasizes user-friendliness by providing accessible quantum dot materials along with comprehensive instructions for constructing high-performance imaging devices. This approach enables healthcare professionals to obtain precise medical images, enhancing the overall efficacy of diagnostic procedures.

TENSIVE

Series A in 2025
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

.Lumen

Venture Round in 2025
Dotlumen is a research startup founded in 2020 and based in Cluj, Romania, focused on enhancing the quality of life for visually impaired individuals. The company develops innovative glasses equipped with a sensory and feedback system that aids users in navigating their environments. By leveraging advancements in artificial intelligence, robotics, and neuroscience, Dotlumen aims to empower blind individuals to better understand and interact with the world around them.

Photon IP

Grant in 2025
Photon IP is a deeptech startup located in Eindhoven, the Netherlands, focused on developing advanced technologies for photonics applications. The company specializes in application-specific semiconductors that cater to various sectors, including wearable electronics and data centers. By providing innovative solutions, Photon IP supports clients in industries such as automotive and telecommunications, aiming to enhance the functionality and efficiency of their products.

GBM Works

Seed Round in 2024
GBM Works B.V., founded in 2016 and headquartered in The Hague, Netherlands, specializes in the installation of offshore wind turbine foundations. The company has developed an innovative method known as the GBM Vibro-drill, which aims to minimize ocean noise during the installation process. This technology not only enhances the efficiency of installing turbine foundations but also addresses environmental concerns by reducing disruption to marine ecosystems and nearby communities. Through its advancements, GBM Works contributes to the growth of the renewable energy sector, facilitating the expansion of offshore operations in a sustainable manner.

INBRAIN Neuroelectronics

Series B in 2024
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Innoventric

Series B in 2024
Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its Trillium™ technology, designed to provide functional tricuspid valve replacement through cross-caval anchoring and a unique multi-valve design. This technology aims to regulate blood flow effectively, thereby enhancing both the lifespan and quality of life for patients. Innoventric has successfully completed over ten implantations of the Trillium™ technology as part of its first clinical trial in Europe and maintains a robust patent portfolio covering its key innovations in tricuspid treatment.

National University of Ireland, Maynooth

Grant in 2024
Maynooth University is internationally recognised for quality and value of Their research and scholarship and Their dedication and commitment to teaching and Their students. Part of the NUI and formally established as an autonomous university in 1997, Maynooth University traces its origins to the foundation of the Royal College of St. Patrick in 1795, drawing inspiration from a heritage that includes over 200 years of education and scholarship. The University is a place of lively contrasts. It is a modern institution, dynamic, rapidly-growing, research-led and engaged, yet grounded in historic academic strengths and scholarly traditions.

.Lumen

Venture Round in 2024
Dotlumen is a research startup founded in 2020 and based in Cluj, Romania, focused on enhancing the quality of life for visually impaired individuals. The company develops innovative glasses equipped with a sensory and feedback system that aids users in navigating their environments. By leveraging advancements in artificial intelligence, robotics, and neuroscience, Dotlumen aims to empower blind individuals to better understand and interact with the world around them.

Qblox

Series A in 2024
Qblox is a Dutch scaleup focused on quantum technology, specializing in the development of control hardware for quantum computers. The company offers patented, modular control systems that integrate hardware and software solutions designed to enhance the management of qubits. By creating a distributed processor architecture, Qblox simplifies experimental setups while improving gate fidelities through advanced electronics that reduce noise and drift. This innovation enables scientists to minimize crosstalk, implement low-latency control flows, and optimize measurement efficiency, addressing significant scientific and engineering challenges in the evolution of quantum computing. Qblox aims to support the transition from prototype quantum computers to powerful computational systems, thereby contributing to the broader advancement of quantum technology.

King's College London

Grant in 2024
King's College London (informally King's or KCL) is a public research university located in London, United Kingdom, and a constituent college of the federal University of London. King's is arguably the third-oldest university in England, having been founded by King George IV and the Duke of Wellington in 1829, receiving its royal charter in the same year. St Thomas' Hospital, which is now a teaching hospital of King's College London School of Medicine, has roots dating back to 1173. In 1836, King's became one of the two founding colleges of the University of London. King's is based in the centre of London and organised into nine academic schools, spread across four Thames-side campuses in central London and another in Denmark Hill in south London. It is one of the largest centres for graduate and post-graduate medical teaching and biomedical research in Europe; it is home to six Medical Research Council centres for <a href="https://www.dissertationcorp.co.uk/">dissertation help</a> , the most of any British university, and is a founding member of the King's Health Partners academic health sciences centre. King's has around 25,000 students and 6,113 staff and had a total income of £587 million in 2012/13, of which £164 million was from research grants and contracts. King's is a world-leading university, currently ranked 19th in the world (6th in the UK and 8th in Europe) in the 2013 QS World University Rankings, and 38th in the world (6th in the UK and 9th in Europe) in the 2013 Times Higher Education World University Rankings. There are currently 12 Nobel Prize laureates amongst King's alumni and current and former faculty. King's is a member of the Association of Commonwealth Universities, the European University Association, the Russell Group and Universities UK. It forms part of the 'golden triangle' of British universities.

Tilkal

Venture Round in 2024
Tilkal is a Paris-based company founded in 2017 that specializes in supply chain traceability through its innovative software platform. This platform utilizes a B2B blockchain network to facilitate secure and verifiable data sharing among various supply chain stakeholders. Tilkal’s software captures traceability data from physical products in a ledger, enabling companies to obtain real-time insights into their supply chains. Customers leverage the platform to address critical questions regarding product location, sourcing risks, ESG commitments, and compliance verification. Notable clients include Danone, Daher, Joone, and the Responsible Mica Initiative, among others. The Tilkal network comprises over 70 independent nodes, with nearly 700 companies actively participating to share and analyze data, thereby enhancing the resilience, sustainability, and ethical standards of their supply chains.

Basemark

Series B in 2024
Basemark Oy is a technology company based in Espoo, Finland, specializing in performance measurement and augmented reality software for various industries, particularly in automotive applications. Founded in 2015, Basemark develops a suite of benchmarking tools that include Basemark ES 3.1 for graphics performance comparisons, Basemark OS II for system-level performance assessment of smartphones and tablets across multiple platforms, and Basemark X for evaluating gaming and graphics performance. Additionally, it offers Browsermark, which tests browser performance on a range of devices, and Basemark CL for measuring OpenCL implementations. In the automotive sector, Basemark provides a comprehensive suite of augmented reality development tools, enabling original equipment manufacturers and suppliers to create and deploy advanced AR applications for vehicle functions. These tools encompass features such as augmented reality navigation, head-up displays, and AI-based spatial computing, enhancing safety and performance in software-defined vehicles.

E-peas

Venture Round in 2024
e-peas SA is a Belgian company that specializes in designing and manufacturing electronic systems that enable energy autonomy for Internet of Things (IoT) applications. Founded in 2014 and based in Mont-Saint-Guibert, the company develops energy harvesting solutions that allow IoT devices to draw power from their environment, including sources such as solar, thermal, vibration, and radiofrequency. e-peas produces energy harvesting power management integrated circuits (PMICs) and low-power microcontrollers that enhance the performance and longevity of batteries in connected devices. By facilitating the efficient use of ambient energy, e-peas aims to reduce the need for frequent battery replacements across various sectors, including home automation, healthcare, and agriculture. The company's innovations contribute to making IoT devices smarter and more energy-efficient, ultimately striving for a future where devices can operate indefinitely without traditional power sources.

Ability Pharmaceuticals

Venture Round in 2024
Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Multiverse Computing

Series A in 2024
Multiverse Computing SL is a software development company based in San Sebastian, Spain, with an additional office in Toronto, Canada. Founded in 2019, the company specializes in creating quantum computing software that addresses complex financial and macro-economic challenges. Its products are tailored for various applications, including portfolio optimization, risk analysis, and market simulation. By leveraging probabilistic and nondeterministic technologies, Multiverse Computing aims to help organizations across diverse sectors such as banking, energy, manufacturing, and logistics navigate the complexities of the second quantum revolution, ultimately providing them with a competitive advantage in their respective industries.

Daze

Series A in 2024
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Palobiofarma

Venture Round in 2024
Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

Heart Aerospace

Series B in 2024
Heart Aerospace AB, founded in 2018 and headquartered in Gothenburg, Sweden, with an additional location in Palo Alto, California, focuses on developing an electric regional airliner aimed at enhancing sustainable transportation for regional travel. The company's flagship aircraft, the ES-19, is designed to accommodate nineteen passengers and boasts an operational range of 400 kilometers. Heart Aerospace seeks to significantly reduce fuel and maintenance costs compared to traditional aircraft while achieving zero operational emissions. The innovative design allows for a low infrastructural footprint, facilitating the use of small airports located near city centers. Heart's objective is to secure certification for the ES-19 for commercial operations by 2026, aligning with its mission to provide affordable and environmentally friendly travel options across the globe.

NETRIS Pharma

Series A in 2023
NETRIS Pharma S.A.S. is a biotechnology company based in Lyon, France, that specializes in identifying and developing therapeutic molecules aimed at treating cancer. The company's innovative approach focuses on targeting dependence receptors, which are trans-membrane proteins that play a crucial role in signaling within cells and regulating tumor development. NETRIS Pharma offers both in vitro and in vivo research services, along with preclinical practices, to advance drug manufacturing for various types of cancer, including breast cancer, lung cancer, glioblastoma, and neuroblastoma. Founded in 2008, the company is dedicated to contributing to the pharmaceutical industry by developing novel cancer therapies.

Antabio

Series B in 2023
Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Ignion

Venture Round in 2023
Ignion is an antenna innovator based in Sant Cugat del Vallès, Spain, founded in 2015. The company specializes in manufacturing multiband, multipurpose antennas that cater to mobile and wireless connectivity requirements. Its product offerings include ready-to-use antennas designed for Internet of Things applications and short-range wireless devices, particularly suited for indoor environments. Ignion's solutions allow clients to seamlessly integrate these antennas into their industrial designs, facilitating efficient connectivity in various applications.

ResoTher Pharma

Grant in 2023
ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

SolasCure

Grant in 2023
SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

VSORA

Grant in 2023
VSORA is an intellectual property provider based in France, specializing in digital signal processing (DSP) technology for chipmakers focused on next-generation digital communications systems, particularly 5G networks. Established in 2015 by a team of experienced DSP engineers, the company offers a powerful multi-core DSP architecture that eliminates the necessity for DSP co-processors, thereby enhancing design flexibility. VSORA's innovative DSP development flow enables collaboration between signal processing engineers and software engineers, allowing them to work within the same environment and share source code, which significantly accelerates the time-to-market for new products. The company's mission is to address technical challenges by optimizing DSP computing power while minimizing power consumption and silicon footprint, thereby improving overall system performance.

FarmInsect

Series A in 2023
FarmInsect GmbH, founded in 2019 and based in Bergkirchen, Germany, specializes in automated insect breeding systems designed to provide a sustainable and efficient source of animal feed. The company focuses on enabling local farmers to produce insect larvae from organic residues, which can be used as protein feed for livestock such as chickens, pigs, and fish. By offering a solution that replaces imported soy and fishmeal with locally sourced insect protein, FarmInsect aims to enhance the sustainability of animal husbandry while ensuring that farmers have a consistent supply of young larvae each week for their feeding needs.

Nanogence

Venture Round in 2023
Nanogence SA, established in 2017 and located in Renens, Switzerland, specializes in the development of innovative material solutions for the construction industry. The company focuses on creating synthetic, tailor-made materials that enhance the performance and sustainability of construction applications, including cement and concrete. By leveraging advanced knowledge in chemistry, material science, and nanotechnology, Nanogence has developed patented additive formulations that significantly improve the binding efficiency of cement and concrete while reducing carbon emissions by up to 50%. This enables manufacturers to achieve valuable cost savings, enhance durability, and contribute to more sustainable construction practices in a rapidly growing global market.

Swisspod Technologies

Grant in 2023
Swisspod Technologies SA is a transport development firm based in Monthey, Switzerland, founded in 2019. The company focuses on designing and developing Hyperloop vessels, which are tube-based transportation systems aimed at providing sustainable and efficient high-speed travel. Swisspod leverages high-quality Swiss engineering to create fully-electric Hyperloop pods that promise scalable and rapid transit between distant cities. The firm emphasizes energy efficiency and economic viability in its innovations, making its capsules both affordable and environmentally friendly. With a team of multidisciplinary experts, Swisspod is dedicated to transforming high-speed travel through its cutting-edge technology.

Microsure

Series B in 2023
Microsure is a medical device company based in Eindhoven, The Netherlands, founded in 2014. It specializes in developing innovative solutions for microsurgery, a field that operates at the limits of physical capabilities. The company's flagship product is a motion stabilizer system designed specifically for microsurgeons, which enhances surgical precision by filtering out tremors and providing exceptional control during procedures. This technology allows for hybrid microsurgical procedures that enable surgeons to utilize their own instruments, thereby reducing costs for hospitals. The Microsure motion stabilizer has demonstrated its effectiveness in clinical trials, including successful operations for lymphedema. By improving the quality of microsurgical procedures, the company aims to expand treatment options for patients and facilitate the development of new, highly accurate surgical techniques.

Xeltis

Series D in 2023
Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels, utilizing a proprietary polymer-based technology called RestoreX. This technology enables the patient's natural healing system to develop tissue that permeates the heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis' restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. The company has secured significant funding from investors such as EQT Life Sciences, Kurma Partners, and the European Investment Bank, totaling over €30 million.

INBRAIN Neuroelectronics

Grant in 2023
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

ONO

Convertible Note in 2023
Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

Scipio Bioscience

Convertible Note in 2023
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Handiscover

Seed Round in 2023
Handiscover Sweden AB, founded in 2014 and based in Malmö, Sweden, operates an online booking platform focused on holiday accommodations for individuals with physical disabilities. This pioneering service features a unique classification system that allows users to filter options based on their specific mobility needs. Handiscover aims to simplify the process of finding accessible vacation rentals, catering to the diverse requirements of its users. Additionally, the platform assists companies and municipalities in gathering and presenting specialized accessibility data, ensuring that individuals with disabilities can easily discover and book suitable accommodations for their travels.

Wooptix

Grant in 2023
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

Wooptix

Series B in 2023
Wooptix S.L., founded in 2014 and headquartered in Madrid, Spain, specializes in advanced imaging technologies. The company develops light field and wavefront phase imaging software that captures comprehensive information about light, utilizing the full resolution of sensors. This innovative platform allows for three-dimensional modulation of images across various camera setups, producing volumetric images and videos with enhanced data points and high frame rates. By focusing on improving human interaction with the environment, Wooptix aims to redefine the way users perceive and engage with their surroundings, offering new possibilities for image quality and post-processing capabilities.

Energy Dome

Series B in 2023
Energy Dome is an Italian company based in Lonate Pozzolo that specializes in long-duration electricity storage using liquid carbon dioxide. The company has developed a low-cost and efficient technology that employs a closed-loop thermodynamic process to store energy, making renewable power more dispatchable. By focusing on energy storage solutions, Energy Dome aims to facilitate the transition to renewable energy and contribute to the decarbonization of the energy industry. Its innovative approach seeks to address climate change challenges by significantly reducing greenhouse gas emissions, thereby promoting a more sustainable future.

ADmit Therapeutics

Venture Round in 2023
ADmit Therapeutics, S.L. is a biotechnology company focused on developing diagnostic tests for the early detection of Alzheimer's disease. Established in 2017 and based in Begues, Spain, the company utilizes an epigenetic analysis of blood samples to identify mitochondrial biomarkers, which are not related to traditional indicators such as ß-amyloid or tau proteins. The test employs next-generation sequencing to analyze various methylcytosines in mitochondrial DNA, providing medical practitioners with an accessible method for detecting early-stage Alzheimer's. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in accelerating the identification of potential curative treatments.

Neuro Event Labs

Convertible Note in 2023
Neuro Event Labs Oy is a Finnish medical technology company founded in 2015 and based in Tampere. The company specializes in developing artificial intelligence-powered software that monitors epilepsy patients both at home and in clinical settings. Its primary product collects and analyzes accurate data on epilepsy seizures through the use of video and various sensors, leveraging computer vision, smart analytics, and machine learning. This data is relayed to healthcare providers, allowing them to make informed treatment decisions tailored to individual patients. The solution has been crafted in collaboration with leading hospitals in Finland, enhancing its reliability and effectiveness in managing epilepsy care.

Plasmacure

Convertible Note in 2023
Plasmacure is a Netherlands-based company that specializes in developing cold plasma technology aimed at treating chronic wounds, particularly diabetic foot wounds. Their patented solution effectively kills bacteria, stimulates cell proliferation, and enhances microcirculation, which helps reduce the risk of amputation. By addressing these critical aspects of wound healing, Plasmacure's technology aims to improve the quality of life for patients suffering from chronic wounds.

EBAMed

Series A in 2023
EBAMed SA is a Swiss startup based in Geneva, established in 2018, that focuses on developing innovative medical technology for treating heart arrhythmias. The company is working on an ultrasound-based device designed to monitor heart motion and facilitate non-invasive ablation therapy using proton beams. This technology aims to provide a safe and effective alternative for patients by allowing real-time synchronization of proton therapy with heart movement. By integrating both hardware and software components, EBAMed's device enhances treatment capabilities for existing proton therapy centers, enabling them to offer advanced, non-invasive treatment options for cardiac patients in an outpatient setting.

TreaTech

Series A in 2023
TreaTech is a Swiss Cleantech company founded in 2015 by engineers from the École Polytechnique Fédérale de Lausanne (EPFL). The company focuses on developing innovative treatment technology aimed at addressing the challenges of wastewater management. Its catalytic hydrothermal gasification (HTG) system provides an eco-friendly solution for the disposal of various liquid wastes, such as sewage sludge, which are typically incinerated or sent to landfills. This advanced thermochemical process transforms these wastes into valuable by-products, including renewable gas, clean water, and mineral salts that can be further upgraded into fertilizers. TreaTech's approach aligns with sustainable development goals and the principles of a circular economy, enabling clients to benefit from efficient wastewater treatment while recycling essential resources.

Sparrow Quantum

Seed Round in 2023
Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

VCG.AI

Grant in 2023
The Intelligence Behind Global Circularity VCG.AI transforms industrial by-products and waste into valuable resources. AI-powered development of circular economy business models with the latest technology, material, market, and regulatory insights. Their proprietary AI solution, the Value Chain Generator®, helps companies, cities, and regions accelerate the transition to a circular economy, through Valorisation of By-products and Waste, Circular Product Development, Regional Circular Opportunities Assessment. When organisations want to better valorise by-products and waste, develop or source circular materials, or enhance circularity in their value chains, VCG.AI analyses thousands of data points to deliver the optimal solution tailored to their specific needs and locations. What once took months or years can now be achieved in just weeks—without the need to hire additional technology or bioeconomy experts. VCG.AI’s ever-expanding system includes: - 650+ validated circular solutions - 150+ different proven valorisation technologies - 3.5 M companies - 4M tons of project-ready organic residuals across Europe VCG.AI is on a mission to accelerate the transition to a circular economy by unlocking circular opportunities for businesses worldwide. Learn more about them at www.vcg.ai.

Naco

Grant in 2023
Naco Technologies Ltd, established in 2009 and headquartered in Riga, Latvia, specializes in the development, manufacturing, and supply of nano-coating technologies. The company offers a range of high-performance, multilayer and multicomponent coatings designed to enhance the durability and efficiency of equipment across various industries, including tooling, automotive, aerospace, and micro-chip manufacturing. These coatings, which include oil-enhanced, wear-protective, thermal barrier, and liquid-repellent varieties, are applied to client-supplied parts, creating ready-to-use coated components. In 2015, Naco Technologies was acquired by the Germany-based Schaeffler Group, further expanding its global reach and resources.

Bluedrop Medical

Venture Round in 2023
Bluedrop Medical, established in 2014 and headquartered in Galway, Ireland, specializes in the development, manufacturing, and commercialization of an IoT-enabled device for early detection of diabetic foot ulcers. Their home-based system scans patients' feet daily, transmitting data to the cloud for analysis via advanced algorithms, which can identify skin abnormalities. This innovative solution aims to reduce the risk of amputation and improve the lives of diabetic patients, with a significant potential market given that up to 25% of diabetics may develop foot ulcers.

Nemysis

Grant in 2023
Nemysis Limited is a specialty pharmaceutical company based in Dublin, Ireland, founded in 2005. The company focuses on addressing unmet needs in nutritional disorders and deficiencies through a staged approach to product development. Nemysis manufactures food supplements, medical matrix products, and prescription items, targeting the same conditions across different market segments. Among its innovative offerings are a gastric and trypsin-resistant glutenous product for oral enzymatic therapy aimed at celiac disease patients, as well as an iron supplement designed to minimize gastrointestinal side effects associated with iron supplementation. Additionally, the company is developing a glutenous medical device that effectively destroys gluten, helping to prevent symptoms in individuals with celiac disease and non-celiac gluten sensitivity.

Samplix

Grant in 2023
Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

nyris

Venture Round in 2023
nyris GmbH is a Berlin-based company that specializes in a visual product search platform, catering to various industries such as retail, e-commerce, industrial, manufacturing, media, entertainment, and financial services. Established in 2015, nyris focuses on providing a more intuitive search experience by allowing users to find products and objects in images and videos through advanced technologies like artificial intelligence and neural networks. This platform is designed to enhance efficiency by delivering search results in under one second, thereby reducing the friction often associated with traditional text-based searches. With a presence in over 50 countries, nyris serves a diverse clientele, enabling them to improve discovery and operational processes. The company is backed by notable investors, including eCapital, IKEA, and Axel Springer.

Samplix

Venture Round in 2023
Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Wingtra

Series B in 2023
Wingtra AG, founded in 2014 and based in Zürich, Switzerland, specializes in the manufacture of professional drones, notably the WingtraOne, a vertical take-off and landing (VTOL) UAV. This drone is designed for high-precision data collection and has applications across various industries, including surveying, agriculture, forestry, and infrastructure management. Since its market introduction in 2017, Wingtra has established partnerships with over 50 major surveying equipment dealers globally, facilitating the adoption of its technology. The WingtraOne can be operated using WingtraPilot software, enabling users to collect survey-grade aerial data that can be transformed into two-dimensional maps and three-dimensional models, thereby enhancing monitoring and inspection capabilities in sectors such as construction, mining, and environmental management.

Sensius

Convertible Note in 2023
Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Sensius

Venture Round in 2023
Sensius B.V., founded in 2015 and based in Rotterdam, Netherlands, specializes in developing advanced thermotherapy systems for treating head and neck cancers. The company's proprietary technology incorporates localized heating through an integrated microwave system, complemented by interactive software, which allows healthcare professionals to enhance traditional cancer treatments such as radiotherapy and chemotherapy. This innovative approach aims to improve patient outcomes and quality of life by mitigating the toxic effects commonly associated with standard therapies. Sensius has successfully treated seventy patients with its device, achieving a complete response rate of 81.8% at 12 weeks post-treatment. Currently, the company is working towards obtaining CE marking for its device, with significant interest from potential buyers, as it also plans to expand its application to other cancer types in the future.

Valo Therapeutics

Grant in 2023
Valo Therapeutics is an immunotherapy company based in Oxford, United Kingdom, with an additional office in Helsinki, Finland. Founded in 2016, the company focuses on developing antigen-coated oncolytic viruses as therapeutic vaccines for cancer treatment. Its primary platform, PeptiCRAd, is an engineered human oncolytic adenovirus designed to stimulate a systemic anti-tumor T cell response. This innovative approach enables the conversion of oncolytic adenoviruses into targeted, tissue-specific cancer vaccines without the need for multiple genetically modified viruses. Additionally, Valo Therapeutics is working on other strategies, such as PeptiENV, to enhance therapeutic responses to enveloped oncolytic viruses across various cancer types. By utilizing tumor-specific peptides, the company aims to elicit a robust adaptive immune response, potentially providing lasting immunity against multiple cancers and improving patient outcomes.

Voiseed

Venture Round in 2023
Voiseed is an Italian startup focused on artificial intelligence for synthetic speech, specifically designed for the video game industry. The company has developed a scalable AI Dubbing Platform that utilizes advanced generative AI technologies to create virtual human voices with expressive emotional nuances and prosody. This cloud-based software enables users to customize vocal expressions and perform multilingual voice conversions, significantly simplifying the dubbing process. By offering a universal voice model and an emotional data set, Voiseed helps creators efficiently design unique voice textures, thereby reducing costs, time, and complexity in various audio-visual projects. The company is actively expanding its features to cater to additional industries beyond gaming.

TILT Biotherapeutics

Venture Round in 2023
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics

Grant in 2023
TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Modvion

Convertible Note in 2023
Modvion AB, founded in 2015 and based in Gothenburg, Sweden, specializes in the design and development of modular wind power towers constructed from renewable composite materials. The company's innovative modular technology simplifies construction logistics by facilitating transportation and installation of towers over 120 meters tall. This approach not only reduces costs associated with traditional steel tower construction but also enhances efficiency in harnessing wind energy. By leveraging engineered wood products, Modvion aims to improve the economic viability of wind power investments for power plant construction businesses, ultimately contributing to a more sustainable energy landscape.

Kvantify

Grant in 2023
Kvantify, founded in 2022 and headquartered in Copenhagen, Denmark, specializes in quantum computing management software aimed at addressing complex computational challenges across various sectors, including life sciences, financial services, and logistics. The company's platform focuses on enhancing drug discovery processes by employing proprietary physics-based methods to improve the quality of compounds tested in laboratories. By providing advanced computational drug technology, Kvantify enables life sciences companies to accelerate small molecule research and obtain actionable results that significantly impact their operations.

N2 Applied

Private Equity Round in 2023
N2 Applied is a Norwegian technology company focused on revolutionizing fertilizer production for farmers. Operating from its headquarters in Oslo/Asker and with a test center in Svene, Norway, along with branches in the Netherlands and the UK, N2 Applied has developed an innovative technology that allows for the local production of fertilizer using liquid organic substrates like slurry or digestate, combined with air and electricity. This process enhances nitrogen content while preventing ammonia loss and reducing emissions, thus promoting a more sustainable farming approach. By utilizing plasma reactors, the company enables farmers to recycle livestock manure into environmentally friendly fertilizer, lowering production costs and increasing crop yields. N2 Applied's scalable solution aims to streamline the fertilizer supply chain, minimizing reliance on fossil fuel-based chemical fertilizers and contributing to on-farm reductions in methane and ammonia emissions.

Ganymed Robotics

Series B in 2023
Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Daze

Convertible Note in 2022
Daze is an engineering startup focused on creating innovative solutions for electric vehicle charging. Its flagship product, DazePlug, is an automatic charging device that utilizes smart charging ecosystems and energy management systems. This technology enables automatic inductive charging, significantly reducing the time required to charge electric vehicles while eliminating the need for manual handling of cables. DazePlug features a retrofit design that is both waterproof and dustproof, ensuring durability and ease of use. By simplifying the charging process, Daze aims to enhance user experience and convenience for electric vehicle owners.

Energy Dome

Grant in 2022
Energy Dome is an Italian company based in Lonate Pozzolo that specializes in long-duration electricity storage using liquid carbon dioxide. The company has developed a low-cost and efficient technology that employs a closed-loop thermodynamic process to store energy, making renewable power more dispatchable. By focusing on energy storage solutions, Energy Dome aims to facilitate the transition to renewable energy and contribute to the decarbonization of the energy industry. Its innovative approach seeks to address climate change challenges by significantly reducing greenhouse gas emissions, thereby promoting a more sustainable future.

iThera Medical

Venture Round in 2022
iThera Medical specializes in advanced biomedical imaging technology, focusing on photonic molecular imaging. Founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, the company collaborates with this research center to enhance its proprietary Multi-Spectral Optoacoustic Tomography (MSOT) technology. This innovative approach provides real-time visualization of anatomical, functional, and molecular information within living tissue, which aids in the detection of tumors and inflammatory diseases. By enabling non-invasive diagnostic capabilities, iThera Medical supports both preclinical and clinical applications, offering significant advancements in medical imaging and patient care.

Resistell

Series B in 2022
Resistell AG, founded in 2018 and located in Muttenz, Switzerland, develops and markets a diagnostic device for antibiotic susceptibility testing. Utilizing nanomotion technology, the device detects the movement of living bacterial cells to assess their resistance to antibiotics, offering a rapid alternative to traditional culture-based methods. This innovative approach allows for timely and accurate identification of the most effective antibiotics for patients, addressing the growing challenge of antibiotic resistance.

Carmat

Grant in 2022
CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

INBRAIN Neuroelectronics

Grant in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Dimenco

Venture Round in 2022
Dimenco B.V. is a Netherlands-based company that specializes in 3D autostereoscopic technology, offering a range of products and services for both professional and consumer markets. Founded in 2010 and operating as a subsidiary of Top Wise International Enterprise Limited, Dimenco develops 3D displays that allow viewers to see different images without the use of special glasses. Their offerings include autostereoscopic displays, software, content conversion, and consultancy services. The company also provides tools such as the DirectX Visualizer and OpenGL Visualizer, which enable users to experience 3D applications on its displays, and the Dimenco 3D Player for playing 3D video clips. By utilizing a lenticular overlay on LCDs, Dimenco's technology enhances visual experiences, bridging the gap between excitement and reality for users.

FOx Biosystems

Grant in 2022
FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Precisis

Grant in 2022
Precisis is a medical technology company based in Heidelberg, Germany, founded in 2004. The company focuses on developing innovative medical devices aimed at treating epilepsy and enhancing patients' quality of life. Their flagship product involves a device that delivers individualized brain stimulation through a surgical procedure. This device is precisely positioned beneath the scalp over the epileptic origin in the brain, allowing for targeted therapeutic currents to be directed at specific areas without direct contact with the brain. This approach aims to provide deep and focused stimulation to effectively manage epilepsy.

TENSIVE

Venture Round in 2022
TENSIVE s.r.l. is a biomedical company based in Milan, Italy, founded in 2012. It specializes in the development of innovative prostheses for natural breast reconstruction and augmentation. The company's products utilize biodegradable synthetic biomaterials and feature an internal micro-architecture that mimics blood vessel structures. These vascularized prostheses aim to enhance the quality of life for patients undergoing treatment for breast cancer, offering a solution that reduces the need for recurrent and costly surgical interventions. Through its focus on advanced biomaterials and design, TENSIVE seeks to provide effective and sustainable options for breast reconstruction.

ELEM Biotech

Pre Seed Round in 2022
ELEM Biotech SL is a biomedical software company based in Barcelona, Spain, that specializes in creating virtual human beings using advanced mathematical modeling and cloud computing. Founded in 2018 by researchers from the Barcelona Supercomputing Center, ELEM has developed Alya Red, a suite of simulation tools designed for the medical device and pharmaceutical industries. Utilizing a Software-as-a-Service model, Alya Red allows for the simulation of cardiovascular and respiratory systems on virtual patients. By integrating high-performance computing, computational biomechanics, and data analysis, ELEM's technology enables biomedical companies and clinicians to improve diagnoses, plan treatments, and optimize drug delivery and medical devices.

Nano4Imaging

Grant in 2022
Nano4Imaging GmbH, founded in 2011 and based in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimal invasive devices, such as catheters and guidewires. The company offers products like MRWire EmeryGlide, a guide wire compatible with magnetic resonance imaging (MRI), and the MagnaFy series, which includes coatings that enhance visibility under MRI, computed tomography (CT), and X-ray imaging. These innovations facilitate medical interventions and therapies, particularly in the treatment of cardiovascular diseases and during radiotherapy, allowing for precise monitoring of medical devices during procedures. By leveraging nanotechnology, Nano4Imaging aims to enhance diagnostic imaging capabilities for healthcare professionals.

Alesi Surgical

Grant in 2022
Alesi Surgical Ltd. specializes in the development and commercialization of laparoscopic surgical smoke handling systems aimed at enhancing the safety and outcomes of surgical procedures. Founded in 2009 and based in Cardiff, United Kingdom, the company emerged as a spin-out from the Welsh Institute for Minimal Access Therapy, benefiting from direct access to experienced surgeons and surgical trainers. Alesi Surgical's innovative products are designed to be portable and applicable in both laparoscopic and robot-assisted surgeries. Utilizing electrostatic precipitation technology, these tools effectively eliminate surgical smoke, ensuring a clear visual field during procedures. Alesi Surgical distributes its products to hospitals across Europe, the Middle East, New Zealand, and Australia.

Reblade

Grant in 2022
Reblade is a climate-focused deep tech startup that specializes in drone-based and AI-assisted repair technologies for wind turbine blades. The company offers innovative robotic solutions aimed at helping wind farm owners and service providers reduce costs, risks, and service time associated with blade erosion repairs. By utilizing patented technology, Reblade enables its clients to enhance their operational efficiency and achieve significant reductions in carbon emissions. As a recipient of various innovation awards, including Eurostars, Eureka, and the EIC, Reblade presents a compelling business case for the wind energy sector. The company is currently seeking impact investors and strategic partners in Europe, India, and the United States to support its mission and expand its reach in the market for advanced erosion repair solutions.

Deep Render

Grant in 2022
Deep Render Ltd. is a London-based AI start-up that originated from the Department of Computing at Imperial College London. The company specializes in developing advanced media compression algorithms using proprietary and patented technology grounded in machine learning research. Its innovative approach focuses on deep learning, density estimation, and unsupervised learning, resulting in state-of-the-art Biological Image Compression that offers at least a 50% efficiency gain over existing standards. Deep Render's technology is notable for being the first AI-based codec capable of real-time video playback, allowing for significant market expansion and cost reduction for users.

ABCDx

Venture Round in 2022
ABCDx SA is a Swiss company founded in 2014 that specializes in the development, validation, and application of biomarker tests for brain injury treatment. The company focuses on creating biomarker panels designed to identify and diagnose patients at risk for severe long-term complications resulting from conditions such as traumatic brain injuries, strokes, and post-stroke infections. The founders are prominent researchers from the University of Geneva and the Vall d’Hebron Research Institute, bringing significant expertise in biomarker discovery and clinical application. They are complemented by a third founder with extensive experience in the diagnostic and pharmaceutical industries, enhancing the company’s capacity to innovate in brain health diagnostics.

IonKraft

Grant in 2022
IonKraft, a German technology company, specializes in plasma coating solutions for multi-material plastic containers. Their innovative plasma-enhanced chemical vapor deposition process enables recyclability in packaging for various industries, including food, pharmaceuticals, and chemicals. By promoting material reduction and reuse, IonKraft aims to enhance performance and lower costs, backed by funding from the German Federal Ministry for Economic Affairs and Energy.

Newronika

Grant in 2022
Newronika is a company focused on restoring brain and body functions through innovative neuro-modulation technologies. It develops therapeutic devices that utilize a retro-activity system to record brain activity and modulate neuro-stimulation. By collecting, analyzing, and interpreting bio-signals, Newronika enables patients to receive timely stimulation, allowing them to engage in normal daily activities and enhance their quality of life. As a spin-off from prominent Italian research institutions, including the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan, Newronika benefits from a multidisciplinary team of experts in various fields such as neuroscience, neurophysiology, biomedical engineering, and neuropsychology.

INBRAIN Neuroelectronics

Venture Round in 2022
INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Ekkono Solutions

Venture Round in 2022
Ekkono Solutions AB, based in Tvååker, Sweden, specializes in machine learning solutions tailored for the Internet of Things (IoT). The company has developed an embedded advanced analytics engine that performs various machine learning techniques directly on connected devices. This technology encompasses the entire workflow, from data input and model training to execution, re-training, and output. Ekkono's solutions are applicable across diverse industries, including energy, telecommunications, automotive, agriculture, healthcare, and housing automation, as well as in consumer IoT applications such as home security systems and smart appliances. By enabling devices to learn their normal operating states, Ekkono's technology facilitates anomaly detection, performance optimization, and predictive maintenance. This edge-based approach allows real-time data processing, minimizing network load by transmitting only relevant information to the cloud. As a result, connected devices become more autonomous and intelligent, enhancing their functionality while reducing dependence on network quality.

Nexdot

Pre Seed Round in 2022
Nexdot specializes in the synthesis, production, and application of advanced semiconductor nanocrystals known as Quantum Dots (QDs), with a focus on nanoplatelets—two-dimensional nanosheet Quantum Dots that exhibit enhanced properties. Founded as a spin-off from a leading academic laboratory in Paris, Nexdot leverages over a decade of research in nanomaterials to create proprietary materials with controlled shape and composition. These innovations are poised to transform various industries, including displays, lighting, energy storage, detectors, and bio-imaging. Additionally, Nexdot is developing quantum pearl encapsulation technology to enhance the integration of quantum plates into existing production processes, thereby ensuring compliance with environmental regulations. The company is comprised of a dynamic team of skilled scientists and seasoned executives, dedicated to advancing innovation in the field of nanotechnology.

Scantrust

Grant in 2022
ScanTrust SA is a Swiss company that specializes in a cloud-based IoT platform aimed at enhancing product and packaging security through unique identifiers. Founded in 2014 and with operations in cities such as Shanghai, Singapore, and Bangkok, ScanTrust provides a suite of tools including a printer portal for packaging partners to integrate secure codes into their processes, and Scan-data, an online portal for real-time business intelligence and supply chain insights. Additionally, the platform enables product authentication and supply chain traceability using QR codes, which can be verified through mobile applications. By protecting brands and facilitating consumer engagement, ScanTrust helps companies navigate the complexities of selling physical products in a connected market.

Carmat

Post in 2022
CARMAT is a France-based medtech company that specializes in the development and manufacture of bioprosthetic artificial hearts aimed at treating patients with severe heart failure. Founded in 2008 and located in Vélizy-Villacoublay, the company produces biocompatible and auto-regulated total artificial hearts that closely mimic the human heart's functionality. These devices are designed for individuals experiencing chronic terminal heart failure classified as NYHA class IV or those suffering from acute terminal heart failure following a major heart attack. CARMAT's innovative solutions target patients who are not suitable for heart transplantation and have exhausted other treatment options, providing a reliable new therapeutic alternative. In addition to the artificial hearts, CARMAT also develops the associated power supply and control systems, including remote diagnosis capabilities.

Cailabs

Series C in 2022
Cailabs is a French deep tech company based in Rennes, specializing in the design and production of photonic solutions that optimize the use of light in various applications. The company focuses on light shaping components, including mode multiplexers and converters for fiber optic networks, utilizing its patented Multi-Plane Light Conversion (MPLC) technology to reshape both single-mode and multi-mode coherent beams. Cailabs offers products tailored for telecommunications research and development, as well as multi-mode fiber link upgrades for enterprise networks. Additionally, the company provides integrated solutions for the industrial laser sector, such as laser beam shapers and combiners for material processing, and mode-selective multiplexers for EDFA arrays. Founded in 2013, Cailabs aims to address critical industrial challenges through its innovative optical components and expertise.

ONO

Series A in 2022
Creating transformative change in urban mobility, making our cities cleaner and more enjoyable. We first focus on urban logistics, moving goods around the city in ways that are sustainable, efficient and cost-effective. Our vehicle and its modular platform system, with easily swappable modular units, meets the needs of city logistics. From moving food to flowers to furniture, the possibilities are endless. ONO’s founders, pioneer in e-mobility solutions, Beres Seelbach, former head of design at Mercedes and Volkswagen, Murat Günak, and light electric vehicle expert and engineer, Philipp Kahle, sought to rethink and reshape modern urban transportation. They put together a forward-thinking group of designers, engineers and creative thinkers who shared their vision of transforming urban mobility. ONO is a Berlin-based e-mobility company introducing a whole new category of emissions-free vehicle: the Pedal Assisted Transporter (PAT), combining the flexibility of a bicycle with the capacity and durability of a van. We offer environmentally friendly urban logistics solutions designed and optimised for cities of today.

ROSI

Series A in 2022
ROSI is a company based in Grenoble, France, that focuses on innovative recycling and revalorization technologies tailored for the photovoltaic industry. The company specializes in recovering ultra-pure silicon and other valuable metals that are typically lost during the manufacturing of photovoltaic cells and at the end of solar panel life cycles. By valorizing silicon waste generated during the solar wafer slicing process, as well as fine silicon particles lost during production, ROSI aims to make the production of photovoltaic modules more sustainable and cost-effective.

Apix Analytics

Venture Round in 2022
APIX Analytics, founded in 2014 and headquartered in Grenoble, France, specializes in developing and marketing advanced gas analyzer systems. The company focuses on creating miniaturized multigas analyzers that leverage nano-silicon technology to enhance chemical analysis across industrial, environmental, and security applications. By integrating traditional analytical processes such as gas sampling, injection, and separation of complex mixtures, APIX Analytics improves the specificity, detection, identification, and quantification of gas compounds. This innovative approach aims to support clients in meeting safety and quality standards in various sectors, particularly in renewable development.

Energy Dome

Venture Round in 2022
Energy Dome is an Italian company based in Lonate Pozzolo that specializes in long-duration electricity storage using liquid carbon dioxide. The company has developed a low-cost and efficient technology that employs a closed-loop thermodynamic process to store energy, making renewable power more dispatchable. By focusing on energy storage solutions, Energy Dome aims to facilitate the transition to renewable energy and contribute to the decarbonization of the energy industry. Its innovative approach seeks to address climate change challenges by significantly reducing greenhouse gas emissions, thereby promoting a more sustainable future.

Positrigo

Series B in 2022
Positrigo AG is a Swiss company based in Zurich that specializes in the development, production, and sales of dedicated brain positron emission tomography (PET) scanners. Founded in 2018, Positrigo focuses on making functional brain imaging accessible for early detection of neurodegenerative diseases, particularly Alzheimer's disease. The company provides advanced scanning solutions that aid in diagnostics, treatment monitoring, and the development of new therapies for conditions such as Lewy body dementia, vascular dementia, and frontotemporal dementia. By enabling early diagnosis in an affordable manner, Positrigo aims to improve patient outcomes and support healthcare professionals in managing these complex medical conditions.

Ostoform

Grant in 2022
Ostoform Limited is a medical device company based in Dublin, Ireland, focused on improving skin health for individuals with ostomies. Founded in 2016 as a spin-out from the University of Limerick, Ostoform develops patented technologies aimed at managing and reducing skin complications associated with ostomies. The company's primary products include a mouldable seal that fits securely around the stoma and FLOWASSIST, which directs stoma output away from the skin. By effectively guiding the corrosive output into the ostomy bag, these products help prevent skin irritation and swelling, enhancing patient comfort and quality of life. Ostoform aims to become a global leader in the ostomy skin health market, leveraging its innovative solutions to address the needs of ostomy patients.

Fineheart

Grant in 2022
Fineheart is a France-based medical device company that specializes in innovative technologies aimed at addressing cardiovascular diseases. The company is developing an implantable cardiac device that is wirelessly powered and fully implantable, designed to provide mechanical circulatory support. This novel device optimizes cardiac output while preserving the heart's natural contractility, thereby enabling patients with heart failure to restore normal cardiac function and improve their quality of life. Fineheart's focus on advanced medical solutions positions it as a key player in the evolving landscape of cardiovascular care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.